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HumanThe oleﬁn ethylene is a ubiquitously found gas. It originates predominantly from plants, combustion
processes and industrial sources. In mammals, inhaled ethylene is metabolized by cytochrome
P450-dependent monooxygenases, particularly by cytochrome P450 2E1, to ethylene oxide, an epoxide
that directly alkylates proteins and DNA. Ethylene oxide was mutagenic in vitro and in vivo in insects
and mammals and carcinogenic in rats and mice. A physiological toxicokinetic model is a most useful tool
for estimating the ethylene oxide burden in ethylene-exposed rodents and humans. The only published
physiological toxicokinetic model for ethylene and metabolically produced ethylene oxide is discussed.
Additionally, existing data required for the development of a future model and for testing its predictive
accuracy are reviewed and extended by new gas uptake studies with ethylene and ethylene oxide in
B6C3F1 mice and with ethylene in F344 rats.
 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction formed ET (mice, [56]; rats, [82]; humans, [75,15,82,34]. ET is the1.1. Sources of ethylene
The oleﬁn ethylene (ET; CAS No.: 74-85-1) is a gas found ubiqui-
tously in the environment. It is produced by microorganisms, fungi,
and plants (see, e.g., [74,40,89]. Mammals exhale endogenouslylargest volume chemical produced globally [1]. It is primarily used
in the production of polymers and industrial chemicals. About 74%
of environmental atmospheric ET was related to natural and 26%
to anthropogenic sources. Important environmental sources of ET
are natural ﬁres and man-made combustion of organic material as
well as releases during its production and use (reviewed, e.g., in
[45,2]. Concentrations of ET in ambient air are generally below
15 lg/m3 (about 13 ppb) in rural areas and can amount to up to
805 lg/m3 in cities [2]. In the air of a fruit store ET concentrations
were in the range of 0.02–3.35 ppm [88]. A concentration of
46 ppm of ET was measured during ﬁreﬁghting [51]. ET concentra-
tions of up to 47 mg/m3 (about 40 ppm)were reported in a Swedish
plastic producing company [41]. In a Canadian ET production facil-
ity, general workplace exposures to ET were below 15 ppm [67].
Field measurements performed at 14 petrochemical facilities in
North America revealed a mean 8-h time weighted average atmo-
spheric ET concentration of 2.6 ppm (range <0.05–2100 ppm). In
two of the 146 samples collected during 4-h periods, average 4-h
concentrations of atmospheric ET were 3200 and 4200 ppm [61].1.2. Biological fate of ET
ET is only slightly soluble inwater (Ostwald coefﬁcient of 0.1198
at 101.325 kPa and 25 C; [81]). Its blood/air partition coefﬁcient,
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[20]. As a consequence, the major part of ET inhaled by rats and
humans was exhaled unchanged, only a minor part was metabo-
lized. The pulmonary retention or the 1.5 times larger alveolar
retention of ET at steady state (criteria for themetabolismof inhaled
gases; see, e.g., [36]) were below 10% in humans and in rats [35,33].
In mammals, ET is biotransformed to ethylene oxide (EO, CAS No.:
75-21-8). The epoxide was detected in ET-exposed mice, rats, and
humans [31,32,60,30,35]. The formation of EO from ET is catalyzed
by cytochrome P450-dependent monooxygenase(s) (CYP) as was
shown in liver microsomes of the same species [83,58].
Hydroxyethyl-adducts to hemoglobin and DNA, which are
characteristic for EO, were quantiﬁed in ET-exposed rodents and
hydroxyethyl-adducts to hemoglobin in ET-exposed humans
(summarized in, e.g., [35]). Metabolic elimination of EO proceeds
in subcellular liver fractions of mice and rats predominantly via
conjugation with glutathione (GSH) mediated by hepatic cytosolic
glutathione S-transferase (GST) as was shown by [11] and [58]. In
human liver subcellular fractions, microsomal epoxide hydrolase
(EH) plays a pivotal role for themetabolic eliminationof EO, too [58].
1.3. Mutagenicity and carcinogenicity of EO
EO, a colorless gas at room temperature (boiling point: 10.8 C
at 101.3 kPa), is a high production volume chemical used primarily
as an intermediate in the synthesis of various chemicals, especially
ethylene glycol. A very minor part is used as fumigant and insecti-
cide and as sterilizing agent, e.g., for food and medical devices (see,
e.g., [46,47,48]). EO is a directly protein- and DNA-alkylating agent
(reviewed in, e.g., [97]). It was mutagenic in vitro in bacteria and
cells of animals and humans and in vivo in mice, rats, monkeys
(reviewed, e.g., in [47]), and Drosophila [66]. Increased frequencies
of micronucleated cells were found in EO-exposed mice, rats, and
humans. In mice and rats, EO was carcinogenic (summarized in,
e.g., [47,48]). IARC [48] evaluated EO as carcinogenic to humans
(Group 1) by taking into account the ‘‘sufﬁcient evidence for the
carcinogenicity of ethylene oxide in experimental animals’’ and
relying ‘‘heavily on the compelling data in support of the genotoxic
mechanism’’ of EO.
1.4. Mutagenicity and carcinogenicity of ET
Despite its metabolism to EO, ET was neither mutagenic in
Salmonella Typhimurium [91] nor mutagenic/genotoxic in rodents
[90,94] nor carcinogenic in F344 rats that were long-term exposed
to ET concentrations of up to 3000 ppm [43]. The negative results
of the latter study agree with the suggestion that the tissue bur-
dens of metabolically formed EO were too low to produce signiﬁ-
cant effects in a standard carcinogenicity study with ET [8,71,94].
1.5. Rationale for developing a physiological toxicokinetic model for ET
and its metabolite EO in rodents and humans
A physiological toxicokinetic (PT) model for ET and its metabo-
lite EO in mice, rats, and humans should reproduce quantitative
differences in the tissue burdens by ET and EO between the three
species. It should assess internal exposures to EO in relation to
external EO concentrations for which dose–responses of carcino-
genic effects were reported in both rodent species. In addition, it
should ‘‘reﬂect interindividual differences in activation and clear-
ance of the reactive epoxides’’ as has been asked by Melnick [63]
when he was dealing with cancer risks from several oleﬁns includ-
ing ET. This statement is most relevant with respect to the kinetics
of EO which is metabolically eliminated by GST class Theta 1
(GSTT1). The enzyme shows genetic polymorphism in humans,
which may result in sub-population-speciﬁc kinetics of EO [87].However, such a PT model has to be validated on experimental
in vivo data in order to be considered as accurate and reliable: over
a range of doses the predicted fate of the chemical (ET) and its tox-
icologically relevant metabolite (EO) in the body (blood, plasma, or
other tissues) should agree with experimental data in laboratory
animals and humans [17].
1.6. Aim of the present work
It was the aim of the present work to review the only published
PTmodel for ET and itsmetabolite EO and to discuss newer data that
will be most useful for the development of a revised PT model and
for testing its predictive accuracy in the EO burden of ET-exposed
B6C3F1 mice, F344 rats, and GSTT1 positive and negative humans.
In addition, some novel gas uptake studies with ET and EO in
B6C3F1mice and with ET in F344 rats are to be presented. They will
serve to validate model-predicted elimination kinetics of ET in both
strains andof EO in B6C3F1mice. A gas uptake studywith EO in F344
rats was not carried out because such a study has already been pub-
lished [55]. F344 rats were used in the carcinogenicity study with
inhaled ET [43], B6C3F1mice and F344 rats in carcinogenicity stud-
ies with inhaled EO (F344 rats: [37,38,59,84]; B6C3F1 mice: [68]).2. Materials and methods
2.1. Chemicals
Synthetic air 5.5, helium 5.0, hydrogen 5.0, oxygen 4.5, nitrogen
5.0, ET 3.5, and EO 3.0 were obtained from Linde,
Unterschleissheim, Germany. Soda lime ‘‘Drägersorb 800Plus’’ was
from Drägerwerk, Lübeck, Germany, and sodium diethyldithiocar-
bamate trihydrate (dithiocarbamate) from Sigma–Aldrich,
Taufkirchen, Germany.
2.2. Animals
Male F344 rats (in vivo studies, body weights: 280–320 g; con-
trol experiments with carcasses, body weights: 232 and 258 g) and
male B6C3F1 mice (body weights: 25–30 g) were from Charles
River Wiga Deutschland, Sulzfeld, Germany. Animal husbandry
and experimental procedures were performed in conformity with
the ‘‘Guide for the Care and Use of Laboratory Animals’’ [65]. In
order to acclimate the animals, groups of 2 rats or 5 mice, respec-
tively, were housed for at least 5 days before use in a Makrolon
type III cage which was placed in an IVC top ﬂow system
(Tecniplast, Buguggiate, Italy). This system provided the animals
with HEPA-ﬁltered air of 22–25 C and 50–60% humidity. A con-
stant 12-h light/dark cycle was maintained in the chamber room.
Animals had free access to standard chow (Nr. 1324 from
Altromin, Lage, Germany) and tap water.
2.3. Inhalation studies in mice and rats
Before carrying out gas-uptake studies with ET or EO in closed
all-glass exposure chambers, it was tested whether the presence
of soda lime—required for adsorbing exhaled CO2—leads to a loss
of the concentration of ET or EO in chamber air. Closed chambers
(about 2.8 L for ET and about 6.4 L for EO) contained 25 g of soda
lime per chamber. The soda lime had been humidiﬁed with urine
and exhaled water by exposing 5 mice per chamber to pure air
for 5 h. After removing the animals from the chambers, initial con-
centrations of ET and EO were adjusted to 1090 ppm and 94 ppm,
respectively, and concentration–time courses were monitored for
about 7 h (both gases). In order to check whether skin and body
of the animals inﬂuence the gas concentration of ET or EO in the
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atmospheric concentration 30.4 ppm) or to EO (initial concentra-
tion 26.5 ppm) in closed soda lime (25 g) containing chambers of
about 2.8 L (ET exposure) or 6.4 L (EO exposure), and the concen-
tration–time courses of ET or EO were monitored up to 7 h. Also,
2 carcasses of F344 rats (average body weight: 245 g) were
exposed for 6 h to ET (initial concentration 30 ppm) in a closed
soda lime (30 g) containing chamber (6.4 L).
For studying the gas uptake of ET or EO, naïve animals were
exposed in closed chambers that contained soda lime for adsorbing
exhaledCO2. The resulting loss of CO2 from the chamber airwas con-
tinuously compensated by oxygen. The exposure system and the
automatic oxygen supply are described in detail in [33]. Five male
B6C3F1mice per group (average bodyweight: 27.5 g) were exposed
for about 7 h to either ET or EO. The ET experiments were started by
injecting deﬁned amounts of the gas into the atmosphere of the
exposure chambers (volume: 2.8 L; amount of soda lime: 25 g) that
resulted at initial concentrations of 1.1, 3.0, 11, 33, 83, 330, 1050,
3110, or 11,200 ppm. Male F344 rats (average body weight: 300 g)
were exposed to ET for 6 h in groups of 2 animals. The exposure
chambers of 6.4 L contained 30 g of soda lime. Initial atmospheric
ET concentrations of 34, 105, 295, 1090, 3110, or 10,500 ppm were
established by injecting the required amount of ET into the chamber
atmosphere. For the gas uptake studies with EO-exposed mice
(groups of 5 animals per exposure experiment; average body
weight: 27.5 g), chambers of 6.4 L were used which contained 25 g
of soda lime. Gaseous EO was injected at initial concentrations of
8.8, 27, 106, 360, 980, or 2700 ppm into the chamber air.
In order to determine the thermodynamic equilibrium between
the animal body and the atmospheric ET concentration (the maxi-
mum enrichment of inhaled ET in the organism), 5 animals of each
of both species were pretreated with dithiocarbamate, an inhibitor
of CYP2E1 (e.g., [42,85]). Of a solution containing 50 mg dithiocar-
bamate per ml of physiological saline, doses of dithiocarbamate of
400 and of 200 mg per kg of body weight were administered
intraperitoneally to mice and rats, respectively, 30 min before
starting the exposures to ET. The pretreated 5 mice (average body
weight: 27.5 g) were exposed together for 2 h in a soda lime (25 g)
containing closed chamber of 0.8 L starting with an initial ET con-
centration of about 10 ppm. The group of 5 rats (average body
weight: 300 g) was exposed for 2.75 h in a soda lime (30 g) con-
taining chamber of 6.4 L. The initial ET concentration in the cham-
ber air was 430 ppm. The relatively small chamber sizes compared
to the animal volumes established a high sensitivity concerning the
loss of the ET concentration in air.2.4. Gas chromatography
Atmospheric concentrations of ET or EO were determined using
gas chromatographs equipped with ﬂame ionization detectors (GC/
FID), gas sample loops, and stainless steel columns (3.5 m  2 mm
ID) packed with Tenax TA (60–80 mesh). Chromatographic separa-
tions were done isothermally. The GC/FID-procedures are
described in detail in [35] (‘‘GC/FID method A’’ for ET and ‘‘GC/
FID method B’’ for EO). Unfortunately, in the cited publication
the column temperature and the carrier gas pressure used for the
determination of ET were given incorrectly. The correct values
were 60 C and 2.5 kg/cm2.3. Results and discussion
3.1. Existing PT model for ET
The only PT model for ET was developed by Csanády et al. [20].
It was used to predict concentration–time courses of ET or EO inET- or EO-exposed rodents or humans and of exhaled EO in ET-ex-
posed rats. The model described also the formation and elimina-
tion of 2-hydroxyethyl adducts to hemoglobin and DNA in ET- or
EO-exposed rodents and humans and, in addition, the endogenous
production of ET in rats and humans. Modeled compartments rep-
resented arterial, venous, and pulmonary blood, muscle, fat, richly
perfused tissues, and the liver as the only metabolizing organ.
Physiological parameters were taken from the literature (most of
them from [5]). Partition coefﬁcients of ET and EO were deter-
mined experimentally. The maximum rate of ET metabolism and
the corresponding apparent Michaelis constant were obtained for
rats by ﬁtting the model to gas uptake data in ET-exposed male
Sprague–Dawley rats [6]. For mice, the maximum rate of ET meta-
bolism was allometrically extrapolated from the rat value using a
surface scaling factor of (body weight)2/3; the value of the apparent
Michaelis constant was the same as in rats, assuming the enzy-
matic properties to be the same in both species. For humans, a
clearance value was gained by model ﬁts to data measured in
ET-exposed volunteers [23,34]. Metabolic elimination of EO was
expressed by a clearance the numerical value of which was derived
by model ﬁts to concentration–time courses of EO in the blood of
EO-exposed F344 rats [11]. For mice and humans, clearance values
of EO elimination were obtained from the rat value by allometric
scaling using a surface factor of (body weight)2/3. Production rates
of endogenous ET were obtained in rats and humans by model ﬁts
to data reported by Denk [23] and Filser et al. [34]. Rate constants
of adduct formation and elimination, required to predict 2-hydrox-
yethyl adducts of hemoglobin and DNA, were taken from the liter-
ature [79,80,25,92].
In order to validate the PT model, predicted concentration–time
courses of ET or EO were compared to measured ones. These were
concentration–time courses of ET in exhaled air of Sprague–
Dawley rats after intraperitoneal administration of ET [6], of
exhaled EO in Sprague–Dawley rats exposed to high ET concentra-
tions (>1000 ppm; [32]), of EO in gas uptake studies in EO-exposed
F344 rats [55] or Sprague–Dawley rats [32], of EO in blood of EO-ex-
posed B6C3F1 mice [12], and of EO in the atmosphere of an expo-
sure chamber during and after EO exposure of (C3H/R1xB110/
R1)F1 hybrid mice [78]. For humans, predicted EO concentrations
in blood and in exhaled air of EO-exposed workers were compared
to datameasured by Brugnone et al. [13,14]. Additionally, predicted
levels of 2-hydroxyethyl adducts of hemoglobin and DNA were
compared with data that had been measured in mice, rats, and
humans exposed to ET (mouse: [96]; rat: [26,96]; human:
[88,53,34]) or EO (mouse: [79,92,93,95]; rat: [72,73,92,93,95];
human: [24,57,4,10]).
Model simulations of concentrations of ET or EO in blood, in
exhaled air, or in the air in gas uptake studies agreed with data
measured in ET- or EO-exposed rodents and humans. Also, pre-
dicted DNA adduct levels in rodents agreed with reported ones.
However, hemoglobin adduct levels were underpredicted in
rodents by a factor of 2–3. Also, concentration–time courses of
exhaled EO that was formed metabolically in rats from inhaled
ET at high exposure concentrations (>1000 ppm) was not predicted
correctly because the initial EO peak could not be described by the
model (Fig. 1). The model could not be improved for metabolically
produced EO because of missing data. For instance, no data had
been published on EO blood levels in ET-exposed mice, rats, or
humans, with the exception of a study in rats [60] the reported
data and methodology of which, however, were questioned [30].
Also missing were mouse-exposure studies with ET and only a
few data had been reported with EO in mice.
In the model of Csanády et al. [20] both EO elimination path-
ways, the EH- and the GST-catalyzed one, were combined in a sin-
gle pathway because it was the main emphasis of the work to
estimate the tissue burdens of EO and the resulting hemoglobin-
Fig. 1. Concentration–time course of metabolically produced ethylene oxide (EO) in
the atmosphere of closed all-glass exposure chambers (6.4 L) each of which
contained two male Sprague–Dawley rats (average body weight: 215 g) that were
exposed for up to 21 h to ethylene at atmospheric concentrations of ET of
>1000 ppm. Symbols: data measured in three independent experiments [32]; solid
line, simulated by the PT model of Csanády et al. [20] under the assumption of the
bioavailability of EO to be 45%.
Table 1
Parameters (mean values) of enzyme-catalyzed and non-enzymatic reactions in liver
subcellular fractions of mice, rats, and humans with ethylene (ET) or ethylene oxide
(EO) as substrates.
Parameter Mouse Rat Human
Formation of EO from ET (microsomal incubations with ET)
VmaxCYP (nmol EO/min/mg
protein)
0.567 0.401 0.219
KmCYP (mmol ET/L suspension) 0.0093 0.031 0.013
VmaxCYP/KmCYP (ll/min/mg
protein)
60.9 13.1 17.2
kinhib (min1) 0.060 0.070 0.098
Hydrolysis of EO (microsomal incubations with EO)
VmaxEH (nmol EO/min/mg
protein)
n.q.; 1.2⁄ n.q.; 1.8⁄ 14.35
KmEH (mmol EO/L suspension) n.q.; 0.20⁄ n.q.; 0.20⁄ 12.74
VmaxEH/KmEH (ll/min/mg
protein)
n.q.; 6.0⁄ n.q.; 9.0⁄ 1.13
khydrol (min1) 9.3 x 104 9.3 x 104 9.3 x 104
EO conjugation with GSH (cytosolic incubations with EO)
VmaxGST (nmol EO/min/mg
protein)
251; 258⁄ 47.7; 52.7⁄ 10.3 (0.00–
25.8)
KmGST (mmol EO/L suspension) 9; 10.4⁄ 9; 13.0⁄ 9
VmaxGST/KmGST (ll/min/mg
protein)
27.9; 24.8⁄ 5.3; 4.05⁄ 1.14 (0.00–
2.87)
kGSH (min1) 3.12 x 103 3.12 x 103 3.12 x 103
All values are from Li et al. [58] except those marked by an asterisk (*), which are
from Brown et al. [11].
Abbreviations: GSH, glutathione; n.q., not quantiﬁed because non-distinguishable
from spontaneous hydrolysis; VmaxCYP, maximum rate of CYP2E1-catalyzed EO
formation from ET; KmCYP, apparent Michaelis constant of the reaction given as ET
concentration; kinhib, ﬁrst-order rate constant of the ET-mediated suicide inhibition
of CYP2E1; VmaxEH, maximum rate of epoxide hydrolase-catalyzed EO hydrolysis;
KmEH, apparent Michaelis constant of the reaction given as EO concentration; khydrol,
ﬁrst-order rate constant of the non-enzymatic hydrolysis of EO; VmaxGST, maximum
rate of GSH S-transferase-catalyzed conjugation of EO with GSH; KmGST, apparent
Michaelis constant of the conjugation reaction given as EO concentration; kGSH,
pseudo ﬁrst-order rate constant of the spontaneous conjugation of EO with GSH at a
GSH concentration of 15 mmol/L in the incubation medium.
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6 h/d) to ET at concentrations of up to 3000 ppm or EO at concen-
trations of up to 100 ppm (mice) or 300 ppm (rats). Depletion of
GSH that was found in mice and rats at high EO concentrations
(both species: [62]; mice: [12]) could not be predicted. Two PT
models developed only for EO in male rats [55] or in mice, rats,
and humans [29] described this effect. In both models, EH and
GST catalyzed EO hydrolysis and EO conjugation with GSH, respec-
tively, were modeled separately. Krishnan et al. [55] obtained the
required enzyme parameters by model ﬁts to in vivo data, whereas
Fennell and Brown [29] used activities of EH and GST to EO that
were derived from data in microsomes and cytosol of various tis-
sues from mice and rats [11] and of livers from humans [29].
3.2. Existing biochemical parameters for model development
Enzyme- and substrate-speciﬁc biochemical parameters (such
as Vmax and Km) determined in subcellular tissue fractions of labo-
ratory animals and humans can be used in a PT model if their valid-
ity to adequately predict the kinetics of chemicals in vivo can be
ensured [49]. In order to establish an experimental basis for the
development of an upgraded PT model for ET and its metabolite
EO, kinetics of the metabolism of ET and EO were investigated in
tissue subcellular fractions of mice, rats, and humans.
3.2.1. ET-related parameters
CYP-mediated metabolism of ET was studied in microsomal
incubations of male B6C3F1 mice, male F344 rats, and humans
and determined as the production of EO [58]. Maximum EO forma-
tion rate (VmaxCYP) was highest in microsomes of mice and lowest
in microsomes of humans. The highest apparent Michaelis con-
stant of the CYP-catalyzed ET oxidation (KmCYP) was found for rats.
It was about 3fold higher than the values for mice and humans
(Table 1).
ET destroys the hepatic CYP that catalyzes its oxidative metabo-
lism by N-alkylation of one of the four pyrrole rings of the pros-
thetic heme [69,70]. Li et al. [58] calculated the elimination rate
constant (kinhib) of the suicide inhibition from ﬁtting modeled con-
centration–time curves to monitored concentration–time courses
of metabolically formed EO in incubations of ET in microsomal sus-
pensions. The obtained values of kinhib (Table 1) were rather high.
They corresponded to half-lives of between 7.1 and 11.6 min.
The ET-oxidizing CYP isoenzyme is primarily CYP2E1 as was
demonstrated in mice by comparing the EO formation in ET-ex-
posed liver microsomes of CYP2E1-knockout animals with that of
their wild-type counterpart [58]. In F344 rats, the importance ofCYP2E1 for the metabolism of ET to EO was shown indirectly by
Fennell et al. [30]. There are hints that CYP2E1 is also most relevant
for the metabolism of ET in humans because the species-speciﬁc
ratios of the values of VmaxCYP/KmCYP to the values of Vmax/Km of
the CYP2E1 activities (determined with chlorzoxazone as sub-
strate; [22]) are very similar in liver microsomes of mice, rats,
and humans.
3.2.2. EO-related parameters
Kinetics of EO metabolismwas investigated in tissue subcellular
fractions prepared from B6C3F1 mice, F344 rats [11,58], and
humans [58]. Metabolism of EO, catalyzed by EH, could be quanti-
ﬁed and expressed as maximum rate of hydrolysis (VmaxEH) and
corresponding Michaelis constant (KmEH) only in microsomes of
humans [58] (Table 1). Using liver microsomes of 5 human donors
(both genders), Fennell and Brown [29] determined a mean EH
activity with EO as substrate of 1.8 nmol/min/mg protein at an
EO concentration of 15.4 mmol/L; however neither Vmax nor Km
values were reported. For this EO concentration, a 4.4 higher EH
activity of 7.9 nmol/min/mg protein can be calculated using the
Michaelis–Menten equation and the values of VmaxEH and KmEH
obtained by Li et al. [58] with pooled microsomes of 25 donors
(Table 1). The cause for the difference is unclear. In liver micro-
somes of mice and rats, Li et al. [58] could not distinguish the
EH-mediated hydrolysis from the spontaneous, non-enzymatic
hydrolysis that is characterized by the rate constant khydrol
(Table 1). Also Brown et al. [11] found very low EH activities
toward EO in liver microsomes of rats and mice (Table 1). The
authors determined VmaxEH at an initial EO concentration of
15 mmol/L. The values of VmaxEH were not larger than the rate of
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The value of KmEH in rats and mice could only be estimated.
EO was eliminated by GST-catalyzed and spontaneous conjuga-
tion with GSH in liver cytosol of the three species (Table 1).
Non-enzymic conjugation of EO with GSH was also described by
Brown et al. [11], but not quantiﬁed. In mouse or rat liver cytosol,
both working groups [11] and [58] determined similar values of
VmaxGST and KmGST. There is also agreement between the values of
VmaxGST and KmGST determined by Li et al. [58] in cytosolic prepara-
tions of human livers and the mean GST activity toward EO of
8.9 nmol/min/mg protein at an EO concentration of 30 mmol/L,
measured by Fennell and Brown [29] in liver cytosol of human
donors. By means of the values of VmaxGST and KmGST and using
the Michaelis–Menten equation, an EO conjugation rate of
7.9 nmol/min/mg protein can be calculated for the EO concentra-
tion of 30 mmol/L. Li et al. [58] did not detect any GST activity with
EO as substrate in cytosol of 2 out of the 13 human donors
(Table 1). The ﬁnding was in agreement with the observation that
10–25% of non-Asians had GSTT1 null genotype [7].
Cytosolic GST activities toward EO were also quantiﬁed in kid-
neys of mice and rats of both sexes and in testes of both species
[11]. There were no statistically signiﬁcant gender differences in
the activities of GST. Mean values of VmaxGST in kidneys of male
mice and rats were 46.4 and 30.1s nmol/min/mg protein, respec-
tively. Mean values of corresponding KmGST were 7.1 (mouse) and
10.8 (rat) mmol/L. In testes, the values of VmaxGST were 17.3
(mouse) and 20.3 (rat) nmol/min/mg protein, those KmGST were
8.1 (mouse) and 9.2 (rat) mmol/L.
3.2.3. Species differences in enzymatic activities
The species differences in the enzymatic activities (Vmax/Km)
concerning the three reactions (Table 1) are consistent with fre-
quent ﬁndings made in subcellular liver fractions that microsomal
epoxidation of small oleﬁns proceeds in humans at lower rates
than in mice, microsomal EH-catalyzed hydrolysis of small
epoxides is faster in humans than in both rodent species, and
GSH conjugation of small epoxides by cytosolic GST occurs at the
highest rates in mice. For epoxidation, see, e.g., Csanády et al.
[18], 1,3-buatiene; Mendrala et al. [64], styrene; Seaton et al.
[77], 1,2-epoxy-3-butene; Golding et al. [39], isoprene, 3,4-
epoxy-3-methyl-1-butene, 3,4-epoxy-2-methyl-1-butene;
Himmelstein et al. [44], 2-chloro-1,3-butadiene. For hydrolysis,
see, e.g., Kreuzer et al. [54] or Csanády et al. [18], 1,2-epoxy-3-
butene; Mendrala et al. [64], styrene-7,8-oxide; Boogaard and
Bond [9], 1,2:3,4-diepoxybutane; Faller et al. [27], propylene oxide;
Himmelstein et al. [44], (1-chloroethenyl)oxirane. For GSH conju-
gation, see, e.g., Kreuzer et al. [54], 1,2-epoxy-3-butene; Faller
et al. [27], propylene oxide. Species differences in the activity of
cytosolic GSTT1 in liver and kidney were investigated by Thier
et al. [86]. The authors used methyl chloride and dichloromethane
as substrates. Of the species investigated—mouse, rat, hamster,
human (conjugators and non-conjugators)—GSTT1 activities were
highest in mice (both organs).
3.3. Existing data for model validation
Filser et al. [35] quantiﬁed EO in venous blood of ET-exposed
mice, rats, and humans at ET concentrations in air ranging from 1
to 10,000 ppm (animals) or from 5 to 50 ppm (humans).
Fig. 2A and B depict concentration–time courses of EO measured
in blood of animals exposed to ET concentrations of 30 ppm and
higher. Also given are the time courses of EO exemplarily shown in
the blood of one of the 4 ET-exposed volunteers (Fig. 2C). Up to con-
centrations of ET of about 100 ppm (animals) and 50 ppm (humans),
EO concentrations in blood increased to plateaus that were reached
2–3 h after starting the exposures. At equal ET concentrations, bloodlevels of EO at plateau were in humans (Fig. 2D) at least 3 times and
6 times lower than in mice (Fig. 2A) and rats (Fig. 2B), respectively.
At 300, 1000, and 10,000 ppm of ET, blood levels of EO in animals
peaked shortly after starting the exposures. Thereafter, they
declined to species-speciﬁc plateaus, the levels of which were simi-
lar regardless of whether the exposure concentration of ET was 300,
1000, or 10,000 ppm. In humans, the plateau levels differed
interindividually by a factor of up to 1.51 (Fig. 2D). Itwas interpreted
to result probably from the polymorphism of GSTT1 because a sim-
ilar difference (factor 1.61)was found between carriers of the GSTT1
positive and GSTT1 null genotype in the EO-characteristic hemoglo-
bin adduct levels of 32 cigarette smokers [28].
ET induced blood levels of EO in rats were also reported by two
other groups. Fennell et al. [30] monitored EO concentrations in
blood of male F344 rats at various time points during 6-h exposures
to 300, 600, and 1000 ppm of ET. At 300 ppm, EO reached a
maximum of about 0.08 lg/ml (1.8 lmol/L) followed by a decrease
to about 0.06 lg/ml (1.4 lmol/L). At 600 ppm, EO increased to a
peak concentration of roughly 0.13 lg/ml (3.0 lmol/L) after 1 h;
then it decreased rapidly at ﬁrst, then more slowly to a ﬁnal EO
concentration of 0.06 lg/ml (1.4 lmol/L). After 1 h of exposure to
1000 ppm of ET, EO reached a maximum concentration of
about 0.11 lg/ml (2.5 lmol/L) followed by a slow decrease to
0.1 lg/ml (2.3 lmol/L) after 6 h. The data of Fennell et al. [30] are
similar to those given in Fig. 2B with the exception that no peak
was seen at 1000 ppm whereas such peaks were found by Filser
et al. [35] at 300, 1000, and 10,000 ppm ET (Fig. 2B). Also in the
studies of Filser and Bolt [32] an EO peak was found in the atmo-
sphere of closed chambers that contained Sprague–Dawley rats
exposed to ET concentrations of >1000 ppm (Fig. 1). Furthermore,
EO peaked in blood of mice exposed to ET concentrations of
between 300 and 10,000 ppm (Fig. 2A). The missing EO peak at
1000 ppm ET reported by Fennell et al. [30] is probably an incorrect
result.
Maples and Dahl [60] determined EO in blood of male F344 rats
that were exposed for 1 h to ET concentrations of 5 or 600 ppm. At
5 ppm, EO concentrations increased continuously to a plateau con-
centration of between 0.05 and 0.1 lg/g blood (1.1–2.3 lmol/L)
reached after 14 min. At 600 ppm, EO rose quickly to a peak con-
centration of 3 lg/g blood (68 lmol/L), reached after about 7 min
of exposure. About 4 to 5 min later, the EO concentration had
dropped to a rather constant value of about 0.5 lg/g (11 lmol/L).
The plateaus and the peak occurred much earlier and the reported
EO concentrations were one order of magnitude higher than those
found later by Fennell et al. [30] and Filser et al. [35]. The cause for
the difference is not known. Fennell et al. [30] assumed problems
of the analytical method used by Maples and Dahl [60] for the
detection of EO.
Maples and Dahl [60] also exposed rats for up to 6 h to an ET
concentration of 600 ppm. A small but signiﬁcant decrease in the
total hepatic CYP content was detected after 20 min (ﬁrst measure-
ment) and a larger one to 68% of the control value after 6 h (second
measurement). The authors explained these results by the suicide
inhibition of the ET-metabolizing CYP. Fennell et al. [30] extended
the study by investigating total CYP content and CYP2E1 activity in
F344 rats at ET exposure concentrations of 300, 600, and
1000 ppm, and additionally, the activities of the major CYP isoen-
zymes in hepatic microsomes of rats exposed to 1000 ppm of ET.
Of the various CYP activities investigated, that of CYP2E1 showed
the only consistent decrease in a concentration- and time-depen-
dent manner. The CYP inactivation resulted from ET itself and
not from its metabolite EO that did not reduce the hepatic CYP con-
tent of rats exposed to 5 ppm of EO [60]. This ﬁnding was in agree-
ment with the observations that epoxides did not inactivate the
CYP isoenzymes that became destroyed while metabolizing the
corresponding oleﬁns (reviewed by [16]).
Fig. 2. Ethylene oxide (EO) in the venous blood of male B6C3F1 mice, male F344 rats, or male nonsmoking Caucasians exposed to constant concentrations of ethylene (ET);
data from Filser et al. [35]. (A) and (B) Concentration–time courses of EO in the blood of mice (A) or rats (B) that were exposed up to 6 h to ET at atmospheric concentrations
ranging from 30 up to 10,000 ppm. Symbols, mean values of EO concentrations measured in the blood of groups of up to three mice or rats immediately at the end of
exposures to ET at concentrations of 30 (s), 100 ( ), 130 (4), 300 (O), 1000 (h), and 10,000 (}) ppm. (C) Concentration–time courses of EO in the blood of a human (volunteer
A in Filser et al. [35] exposed to ET 3 times for 4 h. Symbols: mean values of measured EO concentrations monitored during exposures to ET at target concentrations of 5 (4),
20 (s), or 50 (O) ppm. (D) Plateau concentrations of EO in the blood of 4 volunteers exposed to ET at target concentrations of 0 ppm (control values), 5 ppm, 20 ppm
(volunteers A, B, C, and D), or 50 ppm (volunteers A, B, and C). Symbols: means of the measured plateau concentrations; A (s), B (O), C (4), D (h). Solid lines: linear
regressions through the origin.
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of the studies of Maples and Dahl [60], Fennell et al. [30], and Li
et al. [58] by an interaction between the CYP2E1-mediated forma-
tion of EO from ET, the suicide inhibition of CYP2E1 by ET, and the
physiological turnover of CYP2E1. Immediately after starting an
exposure to a high concentration of ET, the level of the metaboliz-
ing CYP2E1 decreases quickly due to the initial rapid inactivation
by suicide inhibition. Later, a constant and clearly lower level is
reached when the inactivation rate equals the CYP2E1 turnover
rate. Concurrently, the initial rapid increase in EO blood levels
decreases after reaching a maximum because EO metabolism
becomes faster than its shrinking production. The elimination pro-
cess, the rate of which depends on the actual EO concentration,
slows with time until the plateau is reached at which both rates,
EO production and EO elimination, are equal. At low ET concentra-
tions, the turnover rate of CYP2E1 is high as compared to the rate
of its destruction by suicide inhibition. As a consequence, EO in
blood increases continuously until a plateau is attained. The
in vivo data shown in Fig. 2 will be of utmost importance for test-
ing the predictive capacity of a revised PT model for ET in rats,
mice, and humans in whom the GSTT1 positive and negative indi-
viduals can also be reﬂected by the model.3.4. Novel data for model validation
Concentration–time courses monitored in gas uptake studies
are required for estimating metabolic parameters in the intact ani-
mal by ﬁtting a classical compartmental or a PT model to the data
and for testing the quality of a PT model with respect to the used
metabolic parameters of a gaseous substance [76]. Gas uptake
studies with ET [6] and with EO in male Sprague–Dawley rats
[32] were used in the PT model of Csanády et al. [20]. The EO
uptake data in male F344 rats [55] were used in three PT models
[55,20,29]. Bearing in mind that B6C3F1 mice were used in the
inhalation carcinogenicity study with EO and F344 rats in such
studies with ET and EO, it would be meaningful to use data
obtained in theses strains to validate a PT model for ET and EO.
Therefore, gas uptake studies were carried out in the present work
with ET and EO in B6C3F1 mice and with ET in F344 rats.
3.4.1. Gas uptake studies with ET
3.4.1.1. B6C3F1 mice. ET was administered at various initial concen-
trations in the atmosphere of closed chambers (2.8 L), each con-
taining 5 naïve B6C3F1 mice. Fig. 3A shows the resulting
concentration–time courses of ET (empty black circles) monitored
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centrations below 100 ppm, ET metabolism follows ﬁrst-order
kinetics with almost parallel slopes that are steeper than at higher
concentrations. At a ﬁrst glance, this picture seems to agree with
simple saturation kinetics of the ET metabolism. A control experi-
ment without animals revealed that the chambers were gas-tight
and that humidiﬁed soda lime did not inﬂuence the ET concentra-
tion in the chamber air ( and blue line, ﬁtted to the data by
assuming an e-function). The loss of ET over time (calculated
half-life 278 h) resulted most probably from the amount of ET
sampled for GC analysis. The red symbols () together with the ﬁt-
ted e-function (red line) symbolize an ET-exposure experiment
with 5 mouse carcasses. The calculated half-life (166 h) reﬂects a
loss in the atmospheric ET concentration of only 1 ppm within
almost 7 h. From a comparison of the concentration–time courses
of ET seen in the control experiments with those obtained in the
studies with living animals it follows clearly that the dose-depen-
dent slopes of the continuous decreases of ET in the in vivo expo-
sures resulted from intake and metabolism of ET.
In order to analyze the initial intake of ET up to its maximum
enrichment in the body, a gas-uptake experiment was conducted
with 5 mice pretreated with dithiocarbamate for inhibiting
CYP2E1-mediated metabolism of ET (Fig. 3B). The curve, which
was ﬁtted to the measured data, shows a rapid decline followed
by a plateau. The initial decline results from inhalation uptake of
ET by the animals; the plateau is reached when the thermody-
namic equilibrium (Keq) between the ET concentrations in the bod-
ies of the animals and in the air is attained. No further decrease of
ET was seen in contrast to the picture with non-pretreated animals.
It can be regarded as a proof for the effective inhibition of the ET-
metabolism by dithiocarbamate. From the kinetic parameters
describing the curve (see legend to the ﬁgure) and the volumes
of the air space in the chamber (V1, 637.5 ml) and of the exposed
animals (V2, 137.5 ml), the value of Keq of ET for the mouse can
be calculated by the following equation: Keq = [(y(0)  y(1))  V1]/
(V2  y(1))  0.5. The value of the rate constant k (4.888 h1, see
legend to the ﬁgure), which summarizes the intake process in
the experiment, depends on the volumes V1 and V2, the breathingFig. 3. Gas uptake studies with male B6C3F1 mice exposed to ethylene (ET) in closed al
placed in chambers (2.8 L) with initial concentrations of ET of 1.1, 3.0, 11, 33, 83, 330, 10
control experiment with humidiﬁed soda lime solely ( ) and in a control experiment
concentration of 30.4 ppm (). Symbols indicate measured concentrations of ET; dashe
data by assuming e-functions the rate constants of which were 0.00249 h1 (blue line) an
chamber (0.8 L) containing a group of 5 mice (average body weight: 27.5 g) pretreated
Symbols (s) indicate measured concentrations of ET. The solid black line shows t
k = 4.888 h1), ﬁtted to the data by using the program Prism 6 for Mac OS X from Grap
reaching the thermodynamic equilibrium between the ET concentrations in the organistime volumes of the exposed animals, and the rate of transport
of the lipophilic ET by the blood ﬂow to its storage (the adipose
tissue).
3.4.1.2. F344 rats. Fig. 4A depicts the results of the ET gas uptake
studies performed in F344 rats (2 animals per exposure in a closed
chamber of 6.4 L). Dashed lines connect the measured data (s). The
picture resembles that seen in mice. The slopes of the concentra-
tion–time courses decrease with increasing initial ET concentra-
tions. Also plotted in the ﬁgure is a control experiment with 2 rat
carcasses (average body weight: 245 g) that were exposed in a
closed chamber of 6.4 L to ET at an initial concentration of
30 ppm (; red line, ﬁtted e-function). The calculated half-life of
209 h resulted from a decrease in the ET concentration of less than
1 ppm within 6 h. For living rats, exposed at similar conditions to
an initial ET concentration of 34 ppm (Fig. 4A), a half-life of ET in
chamber air of 13.15 h was calculated. The 16-fold shorter half-life
resulted clearly from metabolism of ET.
Also in rats, a gas-uptake experiment was conducted after
inhibiting CYP2E1-mediated ET metabolism by pretreatment with
dithiocarbamate. This procedure revealed the same drastic reduc-
tion of the biotransformation of ET (Fig. 4B) as was observed in
mice. Keq of ET in the rat was calculated from V1 (4870 ml), V2
(1500 ml), y(0) (430.8 ppm), and y(1) (383 ppm)—both concentra-
tions gained from the e-function ﬁtted to the measured data—to
Keq  0.4. The value of the rate constant k was 4.337 h1 (see
legend to the ﬁgure).
3.4.1.3. Comparison with previous studies. Concentration–time
courses of ET similar to those depicted in Figs. 3B and 4B had been
obtained also in male Sprague–Dawley rats pretreated with dithio-
carbamate. From the data, a value of Keq of 0.7 was derived [6].
Using a PT model, Csanády et al. [20] estimated a value of 0.65.
The Keq values of 0.5 (mouse) and 0.4 (rat) calculated from the pre-
sent data do not disagree with the older results.
The concentration–time courses of ET seen in naïve mice and
rats (Figs. 3A and 4A) hint to saturation kinetics of ET in both spe-
cies. From plotting such data (not shown in the original paper) tol-glass chambers. (A) ET uptake by groups of 5 mice (average body weight: 27.5 g)
50, 3110, or 11,200 ppm (s). Also shown are concentration–time courses of ET in a
with 5 mouse carcasses (average body weight: 26.1 g) exposed to ET at an initial
d lines represent connections between data points; straight lines were ﬁtted to the
d 0.00417 h1 (red line). (B) Concentration–time course of ET in the atmosphere of a
with the CYP2E1-inhibitor dithiocarbamate 30 min before start of exposure to ET.
he function y = (y(0)  y(1))  e  kt + y(1) (with y(0) = 10.57 ppm, y(1) = 9.56 ppm,
hpad Software, Inc., San Diego, California. The curve reﬂects the intake of ET until
m and in the air.
Fig. 4. Gas uptake studies with male F344 rats exposed to ethylene (ET) in closed all-glass chambers. (A) ET uptake by groups of 2 rats (average body weight: 300 g) placed in
chambers (6.4 L) with initial target concentrations of ET of 34, 105, 295, 1090, 3110, or 10,500 ppm in air (s). Also shown are concentration–time courses of ET in a control
experiment with 2 rat carcasses (average body weight: 245 g) exposed to ET at an initial concentration of 30 ppm (). Symbols indicate measured concentrations of ET and
dashed lines represent connections between data points. The red straight line was ﬁtted to the data by assuming an e-function the rate constant of which was 0.00332 h1. (B)
Concentration–time course of ET in the atmosphere of a chamber (6.4 L) containing a group of 5 rats (average body weight: 300 g) pretreated with the CYP2E1-inhibitor
dithiocarbamate 30 min before start of exposure to ET (s). Symbols indicate measured concentrations of ET. The line shows the function y = (y(0)  y(1))  e  kt + y(1) (with
y(0) = 430.8 ppm, y(1) = 383 ppm, k = 4.337 h1), ﬁtted to the data by using the program Prism 6 for Mac OS X from Graphpad Software, Inc., San Diego, California. The curve
reﬂects the intake of ET until reaching the thermodynamic equilibrium between the ET concentrations in the organism and in the air.
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of ET metabolism in male F344 rats of 0.24 mg/h/kg body weight,
which is equivalent to 8.5 lmol/h/kg body weight (measured data
not shown in the original publication). Bolt et al. [6] obtained the
same value when analyzing in Sprague–Dawley rats similar ET-up-
take data as the present ones by means of a compartment model.
This value was also used in the PT model of Csanády et al. [20].
Based on the determination of EO in ET-exposed liver microsomal
suspensions, Li et al. [58] calculated maximum in vivo rates of ET
elimination—before suicide inhibition becomes effective—of 42.9
(mouse), 28.9 (rat), and 9.8 (human) lmol/h/kg body weight. The
value for rats is 3.4 times higher than the one obtained by
Andersen et al. [3] and Bolt et al. [6]. In the earlier determinations,
the suicide inhibition, which pretends a lower maximum rate of ET
metabolism, was not taken into account. One cause for the misin-
terpretation of the gas uptake curves at high ET concentrations was
that the initial phase of CYP2E1 inhibition (see [58]) and the phase
of ET enrichment in the organism (see Figs. 3B and 4B) are overlap-
ping. Therefore, it was not possible to recognize the loss of the rate
of ET metabolism. Obviously, precautions have to be taken when
interpreting non-linear concentration–time courses obtained in
gas uptake studies in which normally only the parent compound
(here ET) is determined and not the direct metabolite (here EO)
simultaneously. A reliable kinetic analysis of the ET data shown
in Figs. 3A and 4A requires a PT model in which the species-speciﬁc
CYP2E1 turnover and the rate constant of the ET-dependent suicide
inhibition have to be incorporated. For that reason, an analysis on
the sole basis of the measured concentration–time courses was not
carried out.Fig. 5. Uptake of ethylene oxide (EO) by groups of 5 male B6C3F1 mice (average
body weight: 27.5 g) placed in soda lime (25 g) containing closed all-glass chambers
(6.4 L) with initial target concentrations of EO of 8.8, 27, 106, 360, 980, or 2700 ppm
in air (s). A control experiment without animals but with humidiﬁed soda lime
(25 g) in the chamber is represented by blue symbols ( ) and the blue straight line.
Also shown is a concentration–time course of EO in a control experiment with 5
mouse carcasses (average body weight: 25.8 g) exposed to EO at an initial
concentration of 26.5 ppm (red symbols () and red straight line). Symbols indicate
measured concentrations of EO; dashed lines represent connections between data
points. The straight lines were ﬁtted to the data by assuming e-functions the rate
constants of which were 0.03663 h1 (blue line) and 0.0908 h1 (red line).3.4.2. Gas uptake studies with EO
EO uptake studies were required only for B6C3F1 mice; for F344
rats, such data had already been published [55]. Fig. 5 shows EO
uptake studies in naïve mice and two control experiments, one
without animals and one with EO-exposed mouse carcasses. The
control experiment without animals but with humidiﬁed soda lime
(25 g) in the chamber (6.4 L) showed a decrease of the EO concen-
tration in air that followed ﬁrst-order kinetics with a half-life of EO
of 18.9 h. The EO loss from the chamber atmosphere resulted fromthe base-catalyzed hydrolysis of EO. This conclusion is supported
by results of Filser and Bolt [32] who showed that the half-life of
EO depended on the amount of soda lime. Also, the EO concentra-
tion remained constant over the exposure time in the absence of
soda lime (data not shown). For the ET-exposure experiment with
the carcasses of 5 mice a half-life of 7.6 h was calculated. The loss
of atmospheric EO reﬂects most probably the slow intake of EO
into the carcasses via the skin. It accumulates in the aqueous and
in the lipid phase of the body. For the aqueous phase, a partition
coefﬁcient of EO in Tis-HCl buffer (pH 7.5; 37 C) to EO in air of
62 was reported [83]. The adipose tissue/air partition coefﬁcient
84 J.G. Filser et al. / Chemico-Biological Interactions 241 (2015) 76–86of EO was determined to 43 at 37 C [20]. For the human organism,
Csanády et al. [20] calculated a Keq-value of 53.
In the EO uptake studies with naïve mice, almost linearly
decreasing parallel concentration–time courses were obtained in
the semilogarithmic plot from the smallest initial EO concentration
of 8.8 ppm up to an initial concentration of 360 ppm. This ﬁgure
indicates that there was no saturation kinetics of the metabolic
EO elimination within this concentration range. Somewhat ﬂatter
was the concentration decline following an initial EO concentration
of 980 ppm. At the highest initial concentration of 2700 ppm EO,
the concentration–time course ﬂattened rapidly with the exposure
time. The exposure was stopped after 3.75 h because the animals
showed reduced physical activity. The linear concentration–time
courses agree with in vitro ﬁndings [11,58] which showed that
the GST-catalyzed EO conjugation with GSH was quantitatively
by far the most relevant pathway of EO elimination in livers of
mice and rats. In liver cytosol of both species, this process followed
ﬁrst-order kinetics of up to about 10 mmol EO per liter suspension.
The non-linearity observed in vivo at the highest initial concentra-
tions of EO hints at the depletion of the GSH pool in the liver as a
result of its rapid consumption. A toxicokinetic analysis of the data
presented in Fig. 5 requires a PT model with implemented GSH
turnover as, for instance, was used in the models for butadiene
[52], styrene [19,21], or EO [29]. In these models, the conjugation
of an epoxide with GSH was described by a ping-pong mechanism.
Csanády et al. [19] discussed explicitly the advantages of this
mechanism over the second-order mechanism used in other PT
models.4. Conclusion
The data presented here will serve as an excellent basis for
revising, extending, and validating the previously developed PT
model for ET and EO in mouse, rat, and human [20]. This was
recently exempliﬁed for the rat when demonstrating a revised PT
model for both substances at an international conference held in
Austin, TX [50]. The PT model shall be published together with cor-
responding models for mice and humans (Filser et al.; in
preparation).Conﬂict of Interest
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